Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving antigen-antibody binding – specific binding protein...
Reexamination Certificate
2004-04-14
2008-11-18
Haddad, Maher M (Department: 1644)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving antigen-antibody binding, specific binding protein...
C530S388220, C435S326000, C435S810000, C435S975000
Reexamination Certificate
active
07452677
ABSTRACT:
The present invention provides a monoclonal antibody or a fragment thereof binding to the extracellular I-domain of integrin alpha10beta1 and a hybridoma cell line deposited at the Deutsche Sammlung von Microorganismen und Zellkulturen GmbH under the accession number DSM ACC2583. Furthermore, the present invention also provides a monoclonal antibody or a fragment thereof binding to the extracellular I-domain of integrin alpha10beta1 produced by the hybridoma cell line deposited. Method and uses of the antibody or a fragment thereof in identifying and selecting cells of a chondrogenic nature for treatment purposes, in particular for the identification and isolation of chondrocytes, mesenchymal progenitor cells and embryonic stem cells for tissue engineering of cartilage, or for identifying diagnostic and therapeutic tools in studying the biological role and the structural/functional relationships of the integrin alpha10beta1 with its various extracellular matrix ligands are also included.
REFERENCES:
patent: 4816397 (1989-03-01), Boss et al.
patent: 4816567 (1989-03-01), Cabilly et al.
patent: 4946778 (1990-08-01), Ladner et al.
patent: 5225539 (1993-07-01), Winter
patent: 5514548 (1996-05-01), Krebber et al.
patent: 5565332 (1996-10-01), Hoogenboom et al.
patent: 5585089 (1996-12-01), Queen et al.
patent: 5686059 (1997-11-01), Goetinck et al.
patent: 5698761 (1997-12-01), Pohl et al.
patent: 5698762 (1997-12-01), Dauerman
patent: 5843436 (1998-12-01), Loike et al.
patent: 5853987 (1998-12-01), Guo et al.
patent: 6096873 (2000-08-01), Schaefer et al.
patent: 7029858 (2006-04-01), Lundgren-Akerlund
patent: 2003/0039966 (2003-02-01), Hering et al.
patent: 2003/0055231 (2003-03-01), Ni et al.
patent: 2003/0129685 (2003-07-01), Ni et al.
patent: 2005/0260702 (2005-11-01), Pan et al.
patent: 2006/0099622 (2006-05-01), Ni et al.
patent: 2006/0122373 (2006-06-01), McCarthy et al.
patent: 2006/0123495 (2006-06-01), Gullberg et al.
patent: 2006/0178503 (2006-08-01), Lundgren-Akerlund
patent: 2006/0275287 (2006-12-01), St Croix et al.
patent: 2007/0037206 (2007-02-01), Rosen et al.
patent: 0120694 (1984-10-01), None
patent: 0125023 (1984-11-01), None
patent: 0239400 (1987-09-01), None
patent: 0330506 (1989-08-01), None
patent: 2001-354699 (2001-12-01), None
patent: WO 86/01533 (1986-03-01), None
patent: WO 92/19647 (1992-11-01), None
patent: WO 94/25487 (1994-11-01), None
patent: WO 97/31653 (1997-09-01), None
patent: WO 99/51639 (1999-10-01), None
patent: WO 02/072030 (2002-11-01), None
patent: WO 03/101497 (2003-12-01), None
patent: WO 03/106492 (2003-12-01), None
Owens RJ, Young RJ. The genetic engineering of monoclonal antibodies. J Immunol Methods. 168(2):149-165, 1994.
Male, D., Immunology, An illustrated outline, 2ndedition, Gower Medical Publissing, London, New York, 1991, p. 119.
Shimaoka and Springer. Therapeutic antagonists and conformational regulation of integrin function. Nat Rev Drug Discov. Sep. 2003; 2(9):703-16.
Diamond MS et al. The I domain is a major recognition site on the leukocyte integrin Mac-1 (CD11b/CD18) for four distinct adhesion ligands. J Cell Biol. Feb. 1993;120(4):1031-43.
Lehnert et al., “The integrin alpha 10 subunit: expression pattern, partial gene structure, and chromosomal localization,” Cytogenet. Cell Genet., vol. 87, pp. 238-244, 1999.
Camper et al., “Isolation, cloning, and sequence analysis of the integrin subunit alpha10, a beta1-associated collagen binding integrin expressed on chondrocytes,” J. Biol. Chem., vol. 273, pp. 20383-20389, Aug. 7, 1998.
Hillier et al., Genebank Accession No. N72734, 1996.
Takada et al., “Molecular cloning and expression of the cDNA for alpha 3 subunit of human alpha 3 beta 1 (VLA-3), an integrin receptor for fibronectin, laminin, and collagen,” J. Cell Biol., vol. 115, pp. 257-266, Oct. 1991.
Takada et al., “The primary structure of the alpha 4 subunit of VLA-4: homology to other integrins and a possible cell-cell adhesion function,” EMBO J., vol. 8, pp. 1361-1368, May 1989.
Camper et al., “Integrin alpha2beta1 is a receptor for the cartilage matrix protein chondroadherin,” J. Cell Biol., vol. 138, pp. 1159-1167, Sep. 8, 1997.
Holmvall et al., “Chondrocyte and chondrosarcoma cell integrins with affinity for collagen type II and their response to mechanical stress,” Exp. Cell Res., vol. 221, pp. 496-503, 1995.
Yednock et al., “Alpha 4 beta 1 integrin-dependent cell adhesion is regulated by a low affinity receptor pool that is conformationally responsive to ligand,” J. Biol. Chem., vol. 270, pp. 28740-28750, Dec. 1995.
International Search Report for Application No. PCT/SE99/00544, Jul. 30, 1999.
International Preliminary Examination Report for Application No. PCT/SE99/00544, Jun. 15, 2000.
International Search Report for Application No. PCT/SE2004/000580, Jul. 14, 2004.
Written Opinion of the International Searching Authority for Application No. PCT/SE2004/000580, Jul. 14, 2004.
International Preliminary Report on Patentability for Application No. PCT/SE2004/000580, Jul. 15, 2005.
Armulik, “Studies on the transmembrane signaling of beta1 integrins,” Acta Universitatis Upsaliensis, Comprehensive summaries of Uppsala dissertations from the faculty of medicine 963, pp. 1-92, 2000.
Barry et al., “Biotinylated gene therapy vectors,” Expert Opin Biol Ther., vol. 3, pp. 925-940, Sep. 2003.
Bird et al., “Single-chain antigen-binding proteins,” Science, vol. 242, pp. 423-426, Oct. 21, 1988.
Boudreau et al., “Extracellular matrix and integrin signalling: the shape of things to come,” Biochem J., vol. 339, pp. 481-488, May 1, 1999.
Boulianne et al., “Production of functional chimaeric mouse/human antibody,” Nature, vol. 312, pp. 643-646, Dec. 13, 1984.
Brittberg et al., “Treatment of deep cartilage defects in the knee with autologous chondrocyte transplantation,” N Engl J Med., vol. 331, pp. 889-895, Oct. 6, 1994.
Brittberg, “Autologous chondrocyte transplantation,” Clin Orthop Relat Res., vol. 367 Suppl, pp. S147-S155, Oct. 1999.
Bruder et al., “Growth kinetics, self-renewal, and the osteogenic potential of purified human mesenchymal stem cells during extensive subcultivation and following cryopreservation,” J Cell Biochem., vol. 64, pp. 278-294, Feb. 1995.
Camper et al., “Distribution of the collagen-binding integrin alpha 10beta1 during mouse development,” Cell Tissue Res., vol. 306, pp. 107-116, Oct. 2001.
Caplan et al., “Mesenchymal stem cells: building blocks for molecular medicine in the 21st century,” Trends Mol Med., vol. 7, pp. 259-264, Jun. 2001.
Conrad et al., “GATA transcription in a small rhodamine 123(low)CD34(+) subpopulation of a peripheral blood-derived CD34(−)CD105(+) mesenchymal cell line,” Exp Hematol., vol. 30, pp. 887-895, Aug. 2002.
Daugherty et al., “Polymerase chain reaction facilitates the cloning, CDR-grafting, and rapid expression of a murine monoclonal antibody directed against the CD18 component of leukocyte integrins,” Nucleic Acids Res., vol. 19, pp. 2471-2476, May 11, 1991.
David et al., “Protein iodination with solid state lactoperoxidase,” Biochemistry, vol. 13, pp. 1014-1021, Feb 26, 1974.
Emsley et al., “Structural basis of collagen recognition by integrin alpha2beta1,” Cell, vol. 101, pp. 47-56, Mar. 31, 2000.
Fong et al., “Ongoing normal pregnancy after transfer of zona-free blastocysts: implications for embryo transfer in the human,” Hum Reprod., vol. 12, pp. 557-560, Mar. 1997.
Fong et al., “Comparison of human blastulation rates and total cell number in sequential culture media with and without co-culture,” Hum Reprod., vol. 14, pp. 774-781, Mar. 1998.
Funaro et al., “Monoclonal antibodies in clinical applications,” J Biol Regul Homeost Agents, vol. 10, pp. 72-82, Oct. 1996.
Gough et al., “Rapid and quantitative preparation of cytoplasmic
Cartela R&D AB
Finnegan Henderson Farabow Garrett & Dunner L.L.P.
Haddad Maher M
LandOfFree
Monoclonal antibody capable of binding integrin alpha 10 beta 1 does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Monoclonal antibody capable of binding integrin alpha 10 beta 1, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Monoclonal antibody capable of binding integrin alpha 10 beta 1 will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4021656